
Cardiomyopathy
Latest Content
Latest Videos

More News

A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.

A meta-analysis of HELIOS-B and CARDIO-TTRansform found gene silencers reduced death and CV events, driven by patients not taking stabilizers.

Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

The approval is based on findings from the phase 3 SCOUT-HCM trial.

Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.

A multicenter study found guideline-based grading underestimates tricuspid regurgitation severity and risk in ATTR-CM.

A random survival forest model trained on 850 patients outperformed the Mayo Clinic and National Amyloidosis Centre staging systems for ATTR-CM.

Late-breaking HELIOS-B subgroup data show mortality and CV benefits held regardless of baseline tafamidis use, per results at ESC Congress 2026.

Five-year EXPLORER-LTE data show sustained LVOT gradient reductions and NYHA class improvements in patients with obstructive HCM.

The phase 4 study will track serum transthyretin and other biomarkers in 50 adults with ATTR-CM switching from tafamidis to acoramidis over 6 months.

A secondary analysis of the HELIOS-B trial found that worse left atrial strain was associated with higher risks of mortality and cardiovascular events.

Most Medicare beneficiaries with ATTR-CM waited more than 6 months for diagnosis after heart failure onset, with longer delays among women.

An FDA committee voted 9-3 that available data did not provide substantial evidence of effectiveness for deramiocel in DMD.

Acoramidis attenuated declines in patient-reported health status through 30 months, complementing previously reported survival and hospitalization benefits.

Eplontersen added to standard of care did not significantly reduce cardiovascular death and recurrent events, a study finds.

Left atrial (LA) strain impairment in dilated cardiomyopathy was driven by ventricular dilation, not left bundle branch block.

A retrospective cohort study found stable blood pressure alongside significant reductions in LVOT gradients, regardless of hypertension status.

Claims data show a 4- to 6-fold increase in ATTR-CM diagnoses, with a growing comorbidity burden before diagnosis.

Aficamten improved exercise capacity across submaximal, peak, and recovery measures.

A pooled nonrandomized trial of AAVrh.10hFXN across 17 patients showed reduced LVMI and lower high-sensitivity troponin I levels at all 3 dose cohorts.

Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.

A prospective registry study suggests cardiac MRI scar burden and biomarkers may refine prognostic assessment beyond current sudden cardiac death models.

RBM20 truncating variants are associated with a milder, lower-penetrance form of dilated cardiomyopathy compared with other pathogenic genetic drive.





